|
- IRMS - Nicolae Testemitanu SUMPh
- REVISTE MEDICALE NEINSTITUȚIONALE
- The Moldovan Medical Journal
- The Moldovan Medical Journal
- The Moldovan Medical Journal 2017
- The Moldovan Medical Journal, Vol. 60, No 1, February 2017
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/2729
Title: | Experimental study of new 3-(2-R1 -6-R2 -4-oxyquinoline-3(4H)-yl)alkyl (alkaryl-, aryl) carboxylic acid derivative (PC-66 compound) |
Authors: | Kramar, Hanna |
Keywords: | carboxylic acid derivative (PC-66 compound);analgesic effect;rat pain;models |
Issue Date: | 2017 |
Publisher: | The Scientific Medical Association of the Republic of Moldova |
Citation: | KRAMAR, Hanna. Experimental study of new 3-(2-R1-6-R2-4- oxyquinoline-3(4H)-yl)alkyl (alkaryl-, aryl) carboxylic acid derivative (PC-66 compound). In: The Moldovan Medical Journal. 2017, vol. 60, no 1, pp. 32-34. ISSN 2537-6373. DOI: 10.5281/zenodo.1050953 |
Abstract: | Background: Screening studies have revealed in new 3-(2-R1-6-R2-4-oxyquinoline-3(4H)-yl)alkyl (alkaryl-, aryl) carboxylic acid derivative (PC-66
compound) expressive analgesic properties without any damaging effects on the stomach. Therefore, in-depth study of the pharmacological properties
of PC-66 compound as a pain management agent is considered topical. Objective of the study – to evaluate a pain-killing effect of PC-66 compound
compared to ketorolac and diclofenac sodium on various rat pain models.
Material and methods: In experiments on 101 Wistar male rats (180-210 g) of somatic model (tail-flick) and neuropathic pain model (ligation of the
sciatic nerve), and formalin test (5% formalin solution, 0.1 ml subplantarly) we investigated the antinociceptive activity of the PC-66 compound (1.0 mg/
kg) versus ketorolac (2.4 mg/kg) and diclofenac (4.0 mg/kg) administered intraperitoneally.
Results: In the tail-flick model, PC-66 compound presented significant growth of PT at Hour 1 and Hour 2 by 40.6% and 50.6%, respectively. The analgesia
effect of the test compound was superior to the one of diclofenac sodium, but inferior to ketorolac at Hour 1 and Hour 2, yet surpassed it by duration
of action. In the formalin test model, analgesic effect of compound PC-66 was the most evident in the first (central) phase, and slightly changed the
latent period and duration of the second phase of the test, while diclofenac mostly influenced Phase II (inflammatory) of the formalin test. In the model
of neuropathic pain, compound PC-66 also demonstrated pronounced pain-killing effect: PT of subject rat limb grew on average by 46.7% in 2 hours
following intraperitoneal administration. For this activity, PC-66 was slightly inferior to ketorolac, which caused PT growth by 51.9%.
Conclusions: new 3-(2-R1-6-R2-4-oxyquinoline-3(4H)-yl) alkyl (alkaryl-, aryl) carboxylic acid derivative (PC-66 compound) presented distinct analgesic
effect both in somatic and neuropathic pain models. |
metadata.dc.relation.ispartof: | The Moldovan Medical Journal |
URI: | http://moldmedjournal.md/wp-content/uploads/2017/02/MMJ-60-1-DOI-UDC.pdf http://repository.usmf.md/handle/20.500.12710/2729 https://doi.org/10.5281/zenodo.1050953 |
ISSN: | 2537-6373 2537-6381 |
Appears in Collections: | The Moldovan Medical Journal, Vol. 60, No 1, February 2017
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|